Pharmaceutical marketing research and data analytics companies should not be required to assume responsibility for formal reporting of adverse events (AEs) uncovered during routine pharmaceutical marketing research and data analytics in the U.S. because:
Given that some pharmaceutical and medical device companies have interpreted the regulations to require AE reporting of their research and analytics providers, a marketing research and data analytics company that accepts this responsibility for reporting AEs should, at a minimum, obtain contractual terms that:
Such contract terms extend some measure of legal protection to marketing research and data analytics companies and help to safeguard the ethical integrity of the research process, but they do not overcome the Insights Association’s overriding concerns about the potential risks of requiring routine pharmaceutical marketing research and data analytics studies to serve as a direct instrument of the “pharmacovigilence” process.
The market research and data analytics industry is best-equipped to advance pharmacovigilence by encouraging voluntary reporting by physicians and patients. Recognizing that the industry’s extensive contact with patients and physicians puts us in a unique position to encourage and facilitate AE reporting by those who experience them and the medical professionals who observe them, the Insights Association recommends that research and analytics companies play an indirect role, by reminding respondents of the importance of AE reporting and providing them with information to help them do so.
This information is not intended and should not be construed as or substituted for legal advice. It is provided for informational purposes only. It is advisable to consult with your attorney on the precise scope and interpretation of any laws/regulation/legislation and their impact on your particular business.
Connecticut S.B. 1103 requires the inventory of, and development of policies for, the use of artific...
A new health privacy law in Nevada, while not quite as comprehensive as a lot of the other recent st...
The Senate Judiciary Committee this summer convened a hearing “to lay the ground for legislation to...
Texas Governor Greg Abbott signed S.B. 2105 into law on June 18, 2023, establishing a ...
Rohit Chopra, director of the Consumer Financial Protection Bureau (CFPB), recently said he “will b...
The Pennsylvania Consumer Data Privacy Act (H.B. 1201) is comprehensive privacy legislation modeled ...
0 Comments